Hydration Pharmaceuticals Company Limited

As of December 31, 2025, Hydration Pharmaceuticals Company Limited carries a market capitalization of 2.16M, placing it among publicly traded companies globally. Its enterprise value stands at 484,892.80, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

As of December 31, 2025, Hydration Pharmaceuticals Company Limited has 430.80M shares outstanding.

These figures are as of December 31, 2025. The price-to-sales ratio is 0.52, and the price-to-book ratio stands at 1.02.

These figures are as of December 31, 2025. The EV/Sales ratio of 0.13 reflects the premium investors pay for the company's revenue stream, a useful check when earnings are depressed or negative. These enterprise value multiples are built on an enterprise value of 484,892.80 versus a market cap of 2.16M, with the gap driven by net debt and cash on the balance sheet.

As of December 31, 2025, Hydration Pharmaceuticals Company Limited maintains a current ratio of 2.83, meaning it holds 2.8x the short-term assets needed to cover near-term liabilities.

Over the twelve months ended December 31, 2025, Hydration Pharmaceuticals Company Limited posted a negative return on equity (ROE) of -137.51, meaning shareholder capital produced losses rather than profits. Return on assets (ROA) is negative at -79.59, reflecting losses generated across the asset base. Inventory turnover of 1.13 indicates how many times Hydration Pharmaceuticals Company Limited sells and replaces its inventory over a year, a key working capital efficiency ratio.

As of the close on October 22, 2026, Hydration Pharmaceuticals Company Limited's stock has declined approximately 62.50% over the past 52 weeks. The 50-day moving average sits at 0.00, while the 200-day moving average is 0.01.

Over the twelve months ended December 31, 2025, Hydration Pharmaceuticals Company Limited generated 3.70M in revenue and converted that into -4.29M in net income, yielding earnings per share of -0.01. EBITDA reached -4.71M, while operating income came in at -4.71M.

These figures are as of December 31, 2025. Total book value stands at 2.13M, with working capital of 2.13M providing operational flexibility.

Over the twelve months ended December 31, 2025, Hydration Pharmaceuticals Company Limited posted a gross margin of 55.18, reflecting its pricing power and cost economics. The operating margin of -127.29 and net profit margin of -115.74 provide insight into operational efficiency.

These figures cover the twelve months ended December 31, 2025. Total shareholder yield is negative at -55.87, meaning Hydration Pharmaceuticals Company Limited raised more capital through share issuance and new debt than it returned via dividends and buybacks.

Hydration Pharmaceuticals Company Limited's most recent stock split took place on August 8, 2023 with a 317:327 split ratio.

As of December 31, 2025, Hydration Pharmaceuticals Company Limited has an Altman Z-Score of -29.34, below the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.